Overview

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Status:
Active, not recruiting

Trial end date:
2023-01-17

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Phase:

Phase 2

Details

Lead Sponsor:

Array BioPharma
Pfizer

Treatments:

Infigratinib